Comparison of treatments for preventing lower urinary tract symptoms after BCG immunotherapy of bladder tumors : a systematic review and network meta-analysis
Abstract Background Bacillus Calmette-Guerin (BCG) immunotherapy is the standard adjuvant treatment for high-risk, non-muscle invasive bladder cancer (NMIBC). However, BCG immunotherapy is commonly accompanied by significant lower urinary tract symptoms (LUTS) including symptoms such as urinary urge...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-01-01
|
| Series: | BMC Urology |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12894-024-01675-6 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832571221210824704 |
|---|---|
| author | Zihao Chen Xin Chen Dingchao Li Jingang jian Chang Yao Xuedong Wei Jianquan Hou |
| author_facet | Zihao Chen Xin Chen Dingchao Li Jingang jian Chang Yao Xuedong Wei Jianquan Hou |
| author_sort | Zihao Chen |
| collection | DOAJ |
| description | Abstract Background Bacillus Calmette-Guerin (BCG) immunotherapy is the standard adjuvant treatment for high-risk, non-muscle invasive bladder cancer (NMIBC). However, BCG immunotherapy is commonly accompanied by significant lower urinary tract symptoms (LUTS) including symptoms such as urinary urgency, frequency, dysuria and pelvic pain. These symptoms can undermine treatment adherence and clinical outcomes. In this study, the treatments for preventing LUTS after BCG instillations were compared through a systemic review and network meta-analysis (NMA). Methods Eligible studies were obtained from the PubMed, Web of Science, Embase and Cochrane Library databases. We also searched the references of the included studies. Our protocol followed the preferred reporting items for systematic reviews and meta-analyses (PRISMA) checklist. We performed NMA using Review Manager 5.3 and STATA MP 18.0. Result The analysis included 6 studies with 556 participants. The results of the NMA revealed that celecoxib and prulifloxacin effectivelty reduce the incidence of LUTS including frequency, urgency and dysuria. Phenazopyridine showed the best performance in improving pelvic pain. Conclusion The NMA indicated that medications such as celecoxib, prulifloxacin and phenazopyridine are effective in reducing the incidence of LUTS after BCG immunotherapy of bladder tumors. |
| format | Article |
| id | doaj-art-2777bf3b52644e8882b29a84ef36ca1e |
| institution | Kabale University |
| issn | 1471-2490 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Urology |
| spelling | doaj-art-2777bf3b52644e8882b29a84ef36ca1e2025-02-02T12:44:20ZengBMCBMC Urology1471-24902025-01-0125111010.1186/s12894-024-01675-6Comparison of treatments for preventing lower urinary tract symptoms after BCG immunotherapy of bladder tumors : a systematic review and network meta-analysisZihao Chen0Xin Chen1Dingchao Li2Jingang jian3Chang Yao4Xuedong Wei5Jianquan Hou6Department of Urology, The Fourth Affiliated Hospital of Soochow UniversityDepartment of Urology, The Fourth Affiliated Hospital of Soochow UniversityDepartment of Urology, The Fourth Affiliated Hospital of Soochow UniversityDepartment of Urology, The Fourth Affiliated Hospital of Soochow UniversityDepartment of Urology, The Fourth Affiliated Hospital of Soochow UniversityDepartment of Urology, The First Affiliated Hospital of Soochow UniversityDepartment of Urology, The Fourth Affiliated Hospital of Soochow UniversityAbstract Background Bacillus Calmette-Guerin (BCG) immunotherapy is the standard adjuvant treatment for high-risk, non-muscle invasive bladder cancer (NMIBC). However, BCG immunotherapy is commonly accompanied by significant lower urinary tract symptoms (LUTS) including symptoms such as urinary urgency, frequency, dysuria and pelvic pain. These symptoms can undermine treatment adherence and clinical outcomes. In this study, the treatments for preventing LUTS after BCG instillations were compared through a systemic review and network meta-analysis (NMA). Methods Eligible studies were obtained from the PubMed, Web of Science, Embase and Cochrane Library databases. We also searched the references of the included studies. Our protocol followed the preferred reporting items for systematic reviews and meta-analyses (PRISMA) checklist. We performed NMA using Review Manager 5.3 and STATA MP 18.0. Result The analysis included 6 studies with 556 participants. The results of the NMA revealed that celecoxib and prulifloxacin effectivelty reduce the incidence of LUTS including frequency, urgency and dysuria. Phenazopyridine showed the best performance in improving pelvic pain. Conclusion The NMA indicated that medications such as celecoxib, prulifloxacin and phenazopyridine are effective in reducing the incidence of LUTS after BCG immunotherapy of bladder tumors.https://doi.org/10.1186/s12894-024-01675-6BCGNetwork meta-analysisLUTSBladder cancerImmunotherapy |
| spellingShingle | Zihao Chen Xin Chen Dingchao Li Jingang jian Chang Yao Xuedong Wei Jianquan Hou Comparison of treatments for preventing lower urinary tract symptoms after BCG immunotherapy of bladder tumors : a systematic review and network meta-analysis BMC Urology BCG Network meta-analysis LUTS Bladder cancer Immunotherapy |
| title | Comparison of treatments for preventing lower urinary tract symptoms after BCG immunotherapy of bladder tumors : a systematic review and network meta-analysis |
| title_full | Comparison of treatments for preventing lower urinary tract symptoms after BCG immunotherapy of bladder tumors : a systematic review and network meta-analysis |
| title_fullStr | Comparison of treatments for preventing lower urinary tract symptoms after BCG immunotherapy of bladder tumors : a systematic review and network meta-analysis |
| title_full_unstemmed | Comparison of treatments for preventing lower urinary tract symptoms after BCG immunotherapy of bladder tumors : a systematic review and network meta-analysis |
| title_short | Comparison of treatments for preventing lower urinary tract symptoms after BCG immunotherapy of bladder tumors : a systematic review and network meta-analysis |
| title_sort | comparison of treatments for preventing lower urinary tract symptoms after bcg immunotherapy of bladder tumors a systematic review and network meta analysis |
| topic | BCG Network meta-analysis LUTS Bladder cancer Immunotherapy |
| url | https://doi.org/10.1186/s12894-024-01675-6 |
| work_keys_str_mv | AT zihaochen comparisonoftreatmentsforpreventinglowerurinarytractsymptomsafterbcgimmunotherapyofbladdertumorsasystematicreviewandnetworkmetaanalysis AT xinchen comparisonoftreatmentsforpreventinglowerurinarytractsymptomsafterbcgimmunotherapyofbladdertumorsasystematicreviewandnetworkmetaanalysis AT dingchaoli comparisonoftreatmentsforpreventinglowerurinarytractsymptomsafterbcgimmunotherapyofbladdertumorsasystematicreviewandnetworkmetaanalysis AT jingangjian comparisonoftreatmentsforpreventinglowerurinarytractsymptomsafterbcgimmunotherapyofbladdertumorsasystematicreviewandnetworkmetaanalysis AT changyao comparisonoftreatmentsforpreventinglowerurinarytractsymptomsafterbcgimmunotherapyofbladdertumorsasystematicreviewandnetworkmetaanalysis AT xuedongwei comparisonoftreatmentsforpreventinglowerurinarytractsymptomsafterbcgimmunotherapyofbladdertumorsasystematicreviewandnetworkmetaanalysis AT jianquanhou comparisonoftreatmentsforpreventinglowerurinarytractsymptomsafterbcgimmunotherapyofbladdertumorsasystematicreviewandnetworkmetaanalysis |